New obesity drug candidate RO7795081 enters early safety testing
NCT ID NCT06982131
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 31 times
Summary
This early-stage study tests an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check the drug's safety and how it interacts with two common statins (pitavastatin and rosuvastatin). Participants will receive multiple doses of the drug or a placebo, and researchers will measure side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Plc (LPRA) - Netherlands
RECRUITINGGroningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.